Upcoming Events

There are currently no events scheduled.

Past Events

There are no past events to display.
2017 | 2016 | 2015 | 2014 | 2013
 

DateTitle 
Sep. 26, 2017Juno Therapeutics Closes Follow-on Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
SEATTLE--(BUSINESS WIRE)--Sep. 26, 2017-- Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the closing of its follow-on public offering of 7,015,000 shares of its common stock at a price to the public of $41.00 per share, which includes the exercise in full by the underwriters of the offering of their option to purchase up to an additional 915,00... 
Printer Friendly Version
Sep. 21, 2017Juno Therapeutics Prices $250 Million Follow-on Offering
SEATTLE--(BUSINESS WIRE)--Sep. 21, 2017-- Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the pricing of its follow-on public offering of 6,100,000 shares of its common stock at a price to the public of $41.00 per share. In addition, Juno has granted the underwriters a 30-day option to purchase up to an additional 915,000 shares of common stock.... 
Printer Friendly Version
Sep. 21, 2017Juno Therapeutics Opens New Headquarters and Research Center
Opening celebration and ribbon-cutting highlight advancements in cell therapy and Juno’s investment in scientific advancement SEATTLE--(BUSINESS WIRE)--Sep. 21, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today unveiled its new headquarters and research facility, located in the heart of South Lake Union in Seattle. The new headqua... 
Printer Friendly Version
Sep. 20, 2017Juno Therapeutics Launches Follow-on Offering
SEATTLE--(BUSINESS WIRE)--Sep. 20, 2017-- Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the launch of a proposed follow-on public offering of $225 million of shares of its common stock. In addition, Juno expects to grant the underwriters a 30-day option to purchase up to an additional $33.75 million of shares of its common stock. Juno intends ... 
Printer Friendly Version
Aug. 31, 2017Juno Therapeutics to Present at September 2017 Investor Conferences
SEATTLE--(BUSINESS WIRE)--Aug. 31, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentations at two investor conferences in September. The presentations will feature a business overview and update by Steve Harr, Juno’s Chief Financial Officer and Head of Corporate Development. Juno will present at Citi’s 12th Annual Biotech Conference at 12:00 p.m. Eastern Time (ET) on Thursday, September 7, ... 
Printer Friendly Version
Aug. 08, 2017Juno Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference
SEATTLE--(BUSINESS WIRE)--Aug. 8, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentation at the 2017 Wedbush PacGrow Healthcare Conference at 3:40 p.m. ET on Tuesday, August 15, 2017. The presentation will feature a business overview and update by Steve Harr, Juno’s Chief Financial Officer and Head of Corporate Development. The webcast will be accessible on the Investor Relations page of Juno's ... 
Printer Friendly Version
Aug. 03, 2017Juno Therapeutics Reports Second Quarter 2017 Financial Results
- Presented promising JCAR017 data in NHL with 66% (21/32) overall response and 50% (16/32) complete response at three months in core group moving to pivotal trial - - 2% (1/44) experienced severe CRS and 18% (8/44) experienced severe NT - - Completed JCAR017 commercial manufacturing process lock - - Eleven product candidates in clinical trials against eight different targets - - 2017 cash burn guidance reaff... 
Printer Friendly Version
Jul. 27, 2017Juno Therapeutics to Report Second Quarter 2017 Financial Results on Thursday, August 3
SEATTLE--(BUSINESS WIRE)--Jul. 27, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO) will announce financial results for the second quarter 2017 on Thursday, August 3, 2017, after the close of U.S.-based financial markets. Following the announcement, Juno management will host a conference call and live webcast to provide a business update and discuss financial results beginning at 2:00 p.m. Pacific Time (PT) / 5:00 p.m. Eastern Time (ET). Anal... 
Printer Friendly Version
Jun. 17, 2017Juno Therapeutics Presents TRANSCEND NHL 001 Trial Data at International Conference on Malignant Lymphoma
– 66% (21/32) overall response and 50% (16/32) complete response at three months in core group moving to pivotal trial; of those patients in response at three months, 90% (9/10) continue in response at six months – 66% (29/44) of patients experienced no cytokine release syndrome or neurotoxicity in core group moving into pivotal trial – 18% (8/44) of core group patients experienced severe neurotoxicity and 2% (1/44) experienced severe cyt... 
Printer Friendly Version
Jun. 14, 2017Court Decides It Lacks Jurisdiction Before FDA Approval Occurs
SEATTLE--(BUSINESS WIRE)--Jun. 14, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, announced today that the U.S. District Court for the District of Delaware decided it lacked jurisdiction at this time over a lawsuit filed against Kite Pharma, Inc., citing the absence of evidence that an FDA approval decision of Kite’s lead product candidate axicabtagene... 
Printer Friendly Version
Jun. 06, 2017Juno Therapeutics to Present at the Goldman Sachs 38th Annual Global Healthcare Conference
SEATTLE--(BUSINESS WIRE)--Jun. 6, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentation at the Goldman Sachs 38th Annual Global Healthcare Conference at 10:00 a.m. PT on Tuesday, June 13, 2017. The presentation will feature a business overview and update by Hans Bishop, Juno’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of Juno’s website ... 
Printer Friendly Version
Jun. 05, 2017Juno Therapeutics Presents Updated TRANSCEND NHL 001 Trial Data Demonstrating High Durable Response Rates in Patients with Relapsed or Refractory CD19+ Aggressive Non-Hodgkin Lymphoma
– First multicenter CAR T trial to treat a wide range of patients with aggressive relapsed or refractory NHL excluded from other trials – 66% (21/32) overall response rate and 50% (16/32) complete response at three months in core analysis group moving into pivotal trial; 90% (9/10) of those patients with a response at three months continuing in response at six months – 18% (8/44) of patients experienced severe neurotoxicity and 2% ... 
Printer Friendly Version
May. 23, 2017Juno Therapeutics Appoints Jay Flatley to Board of Directors
SEATTLE--(BUSINESS WIRE)--May 23, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced it has appointed Jay Flatley to its Board of Directors. Mr. Flatley is Executive Chairman of Illumina, Inc. A successful entrepreneur, Mr. Flatley brings to Juno’s board his considerable experience building a highly successful and innovative ... 
Printer Friendly Version
May. 17, 2017Juno Therapeutics to Present Key Clinical Data Updates on JCAR017 and JCAR014 at the 2017 American Society of Clinical Oncology Annual Meeting
SEATTLE--(BUSINESS WIRE)--May 17, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced that it will present key clinical updates in partnership with its collaborators on its investigational products JCAR017 and JCAR014 at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2017 in Chicago, Illinois, June 2-6. ... 
Printer Friendly Version
May. 09, 2017Juno Therapeutics to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
SEATTLE--(BUSINESS WIRE)--May 9, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentation at the Bank of America Merrill Lynch 2017 Health Care Conference at 3:40 p.m. PT on Tuesday, May 16, 2017. The presentation will feature a business overview and update by Steve Harr, Juno’s Chief Financial Officer and Head of Corporate Development. The webcast will be accessible on the Investor Relations page of Jun... 
Printer Friendly Version
May. 04, 2017Juno Therapeutics Reports First Quarter 2017 Financial Results
– Initiated five trials with new binders, technologies, and targets – – 2017 cash burn and operating burn guidance reaffirmed – – Added key talent to leadership team – – Eleven product candidates in clinical trials against eight different targets – – Strong cash position of $850.7 million – – Conference call today at 5:00 p.m. Eastern Time – SEATTLE--(BUSINESS WIRE)--May 4, 2017-- Juno Therapeutic... 
Printer Friendly Version
Apr. 27, 2017Juno Therapeutics to Report First Quarter 2017 Financial Results on Thursday, May 4
SEATTLE--(BUSINESS WIRE)--Apr. 27, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO) will announce financial results for the first quarter 2017 on Thursday, May 4, 2017, after the close of U.S.-based financial markets. Following the announcement, Juno management will host a conference call and live webcast to provide a business update and discuss financial results beginning at 2:00 p.m. Pacific Time (PT) / 5:00 p.m. Eastern Time (ET). Analysts... 
Printer Friendly Version
Apr. 19, 2017Juno Therapeutics Appoints Rupert Vessey to Board of Directors
SEATTLE--(BUSINESS WIRE)--Apr. 19, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced it has appointed to its Board of Directors Dr. Rupert Vessey, President of Research and Early Development of Celgene Corporation. Dr. Vessey brings significant drug development capabilities to the Juno Board. Before joining Celgene in Januar... 
Printer Friendly Version
Apr. 17, 2017Juno Therapeutics Appoints Sunil Agarwal as President of Research and Development
Experienced executive addition with proven leadership and drug development expertise in emerging fields of medicine SEATTLE--(BUSINESS WIRE)--Apr. 17, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced it has appointed Sunil Agarwal, M.D., as President of Research and Development. With Dr. Agarwal’s appointment, Juno will bring R... 
Printer Friendly Version
Mar. 01, 2017Juno Therapeutics Reports Fourth Quarter and 2016 Financial Results
– Nine product candidates in clinical trials against eight different targets – – Pivotal trial for JCAR017 in r/r DLBCL expected to start in 2017 – – Phase I JCAR017 demonstrates 80% overall response and 60% complete response in r/r DLBCL – – Discontinuing development of JCAR015 in r/r adult ALL to focus on defined cell product in this setting – – 2016 year end cash position of $922.3 million – – 2017... 
Printer Friendly Version
Feb. 28, 2017Juno Therapeutics to Present at March 2017 Investor Conferences
SEATTLE--(BUSINESS WIRE)--Feb. 28, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentations at two investor conferences in March. The presentations will feature a business overview and update. Hans Bishop, Juno’s President and Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference at 10:40 a.m. ET on Tuesday, March 7, 2017. ... 
Printer Friendly Version
Feb. 22, 2017Juno Therapeutics to Report Full Year and Fourth Quarter 2016 Financial Results on Wednesday, March 1
SEATTLE--(BUSINESS WIRE)--Feb. 22, 2017-- Juno Therapeutics, Inc. (NASDAQ:JUNO) will announce financial results for the fourth quarter and year ended December 31, 2016, on Wednesday, March 1, 2017, after the close of U.S.-based financial markets. Following the announcement, Juno management will host a conference call and live webcast to provide a business update and discuss financial results beginning at 2:00 p.m. Pacific Time (PT) / 5:00 p.m. Eastern ... 
Printer Friendly Version
Jan. 27, 2017Juno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development Operations
Experienced executive brings demonstrated operational excellence to Juno, will lead newly formed group focused on development operations SEATTLE--(BUSINESS WIRE)--Jan. 27, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the appointment of Corsee D. Sanders, Ph.D., as Executive Vice President and Head of Development Operations, effect... 
Printer Friendly Version
Jan. 03, 2017Juno Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
SEATTLE--(BUSINESS WIRE)--Jan. 3, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentation at the 35th Annual J.P. Morgan Healthcare Conference at 4:30 p.m. PT on Tuesday, January 10, 2017. The presentation will feature a business overview and update by Hans Bishop, Juno’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of Juno's website at www.... 
Printer Friendly Version